hotspot -WSS

hotspot

author：fashion 2025-09-30 06:09:20 - browse：6289

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： White House calls on federal agencies to crack down on AI abuses

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

CDC director unscathed in first congressional testimony

30 years of 'Listening to Prozac'

Flagship Pioneering launches a new biotech in two countries

Rep. Raul Ruiz on the physician shortage and more

J&J to emphasize cancer drugs, stop much of its vaccine research

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

BIO selects John Crowley as new CEO

In age of alternative facts, a scholarly course on calling out crap

Extreme heat events are a public health emergency

How to save PrEP access — and even expand it

J&J to emphasize cancer drugs, stop much of its vaccine research

Heart attack and stroke risk calculators need revising

Diversify hospital leadership teams to protect BIPOC patient health

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

hotspot

Will General Catalyst be the first of many hospital takeovers?

Organ aging and disease risk measured by new blood test

Organ aging and disease risk measured by new blood test

UCSF medical school apologizes for unethical prisoner experiments

BIO selects John Crowley as new CEO

Abortion clinic in Cancun will cater to Americans

leisure time

focus

focus

Wikipedia